Immune peptide enhancement of peptide based vaccines

Frontiers in Bioscience

Volumn 10, Issue 1, 2005, Pages 478-482

  Rosenthal, Ken S ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Epitope Enhancement; Immunomodulation; Peptide Vaccines; Review

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; LIPOSOME; MACROPHAGE ACTIVATING FACTOR; PEPTIDE; TOXOID; VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CROSS PRESENTATION; CYTOKINE PRODUCTION; EPITOPE MAPPING; EXPERIMENTAL DESIGN; IMMUNE RESPONSE; IMMUNE SYSTEM; INTERFERON PRODUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

BACTERIA (MICROORGANISMS);

EID: 17444374626     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1543     Document Type: Article

References (36)

1. Takahashi, H.: Antigen presentation in vaccine development. Comparative immunology microbiology and infectious diseases 26, 309-328 (2003)
2. Gatti, E. & P. Pierre:. Understanding the cell biology of antigen presentation: the dendritic cell contribution. Curr Opin Cell Biol 15, 468-473 (2003)
3. Ackerman, A.L.: Cellular mechanisms governing cross-presentation of exogenous antigens. Nature Immunology 5,, 678-684 (2004)
4. Mosmann, T.R. & S. Sad: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17, 138-146 (1996)
5. Chtanova, T. & C.R. Mackay: T cell effector subsets: extending the Th1/Th2 paradigm. Adv Immunol, 78, 233-266 (2001)
6. Kemp, M., T.G.Theander, & A. Kharazmi: The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today 17, 13-16 (1996)
7. Kamogawa, Y., L.A. Minasi, S.R. Carding, K. Bottomly, & R.A. Flavell: The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75, 985-995 (1993)
8. Szabo, S.J., B.M. Sullivan, S.L. Peng, & L.H. Glimcher: Molecular mechanisms regulating ThI immune responses. Annu Rev Immunol 21, 713-758 (2003)
9. Constant, S.L. & K. Bottomly:. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15, 297-322 (1997)
10. Kaya, Z., K.M. Dohmen, Y. Wang, J. Schlichting, M. Afanasyeva, F. Leuschner, & N.R. Rose: Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 168, 1552-1556 (2002)
11. Karlsson, H., P. Larsson, A.E. Wold, & A. Rudin: Pattern of cytokine responses to gram-positive and gram-negative commensal bacteria is profoundly changed when monocytes differentiate into dendritic cells. Infect Immun 72, 2671-2678 (2004)
12. Lopez, C.B., A. Fernandez-Sesma, J.L. Schulman, & T.M. Moran: Myeloid dendritic cells stimulate both Th1 and Th2 immune responses depending on the nature of the antigen. J Interferon Cytokine Res 21, 763-773 (2001)
13. Palucka, K. & J. Banchereau: How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol 14, 420-431 (2002)
14. Granucci, F., S. Feau, I. Zanoni, N. Pavelka, C. Vizzardelli, G. Raimondi, & P. Ricciardi-Castagnoli: The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis 187 Suppl 2, S346-350 (2003)
15. Shortman, K. & Y.J. Liu: Mouse and human dendritic cell subtypes. Nat Rev Immunol 2, 151-161 (2002)
16. John, B., D. Rajagopal, A. Pashine, S. Rath, A. George, & V. Bal: Role of IL-12-independent and IL-12-dependent pathways in regulating generation of the IFN-gamma component of T cell responses to Salmonella typhimurium. J Immunol 169, 2545-2552 (2002)
17. Steinkasserer, A: Dendritic Cells and Virus Infection. Current topics in microbiology and immunology 276 (2003)
18. Marciani, D.J: Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug discovery today 8, 934-943 (2003)
19. Kopp, E. & R. Medzhitov: Recognition of microbial infection by Toll-like receptors. Current opinion in immunology 15, 396-401 (2003)
20. Takeda, K., T. Kaisho, T. & S. Akira: Toll-like receptors. Annu Rev Immunol 21, 335-376 (2003)
21. Beutler, B: Innate immune responses to microbial poisons: discovery and function of the Toll-like receptors. Annual review of pharmacology and toxicology 43, 609-628 (2003)
22. Flower, D.R: Towards in silico prediction of immunogenic epitopes. Trends Immunol 24, 667-674 (2003)
23. Hunter, R.L: Overview of vaccine adjuvants: present and future. Vaccine 20 Suppl 3, S7-12 (2002)
24. Tam, J.P: Recent advances in multiple antigen peptides. J Immunol Methods 196, 17-32 (1996)
25. Rose, K., W. Zeng, L.E. Brown, & D.C. Jackson: A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol Immunol 32, 1031-1037 (1995)
26. Sadler, K. & J.P. Tam: Peptide dendrimers: applications and synthesis. J Biotechnol 90, 195-229 (2002)
27. Zimmerman, D., K.F. Bergmann, K.S. Rosenthal, & D.A. Elliott: A new approach to T-cell activation: natural and synthetic conjugates capable of activating T-cells. Vaccine Research 5, 91-102 (1996)
28. Zimmerman, D., S. Morris, D. Rouse, K.F.W. Worthington, D.A. Elliott, D.A. & K.S. Rosenthal: Immunization with peptide heteroconjugates primes a T-helper cell type-1 associated antibody (IgG2a) response that recognizes the native epitope on the 38 kDa protein of Mycobacterium tuberculosis. Vaccine Research 5, 103-118 (1996)
29. Rosenthal, K.S., H. Mao, W.I. Home, C. Wright, & D. Zimmerman: Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17, 535-542 (1999)
30. Goel, N., Q. Rong, D. Zimmerman, & K.S. Rosenthal: A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 21, 4410-4420 (2003)
31. Zimmerman, D H, J.P. Lloyd, D. Heisey, M.D. Winship, M Siwek, E. Talor, & P.S. Sarin: Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1 (SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain. Vaccine 19, 4750-4759 (2001)
32. Gillogly, M.E., N.L. Kallinteris, M. Xu, J.V. Gulfo, R.E. Humphreys, & J.L. Murray: Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53, 490-496 (2004)
33. Humphreys, R.E., S. Adams, G. Koldzic, B. Nedelescu, B., E. von Hofe & M. Xu: Increasing the potencv of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18, 2693-2697 (2000)
34. Gillogly, M. E., N.L. Kallinteris, M. Xu, J.V. Gulfo, R.E. Humphreys, & J.L. Murray: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21, 4128-4132 (2003)
35. Xu, M., J. Li, J.V. Gulfo, E. Von Hofe, & R.E. Humphreys: MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 54, 39-44 (2001)
36. del Guercio, M F, J. Alexander, R.T. Kubo, T. Arrhenius, A. Maewal, E. Appella, S.L. Hoffman, T. Jones, D. Valmori, K. Sakaguchi, H.M. Grey, & A. Sette: Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15, 441-448 (1997)